Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SPI Pharma launches Mannogem® XL mannitol, enabling production of difficult-to-compress and problematic formulations

SPI Pharma
Posted on: 09 Oct 18
SPI Pharma launches Mannogem® XL mannitol, enabling production of difficult-to-compress and problematic formulations

PR Newswire

WILMINGTON, Del., Oct. 9, 2018

WILMINGTON, Del., Oct. 9, 2018 /PRNewswire/ -- SPI Pharma introduces Mannogem® XL mannitol to the international pharmaceutical market. It is an innovative approach to mannitol, designed to improve the formulation experience and enhance formulation performance. It is a multifunctional, compendial grade of direct compression mannitol that provides superior compression and disintegration properties.

Sarath Chandar, Chief Scientific Officer, said, "Mannogem XL provides significantly higher compactibility compared to competitive alternatives while ensuring improved stability and dissolution of APIs, especially Class II and Class IV APIs."

Customers will see productivity improvements from development to manufacture, resulting in major gains in final dosage form consistency. Patients will enjoy a positive experience when taking medication, leading to compliance with their dosing regimen and higher satisfaction among caregivers/prescribers.

Chandar continued, "SPI's Applied Innovation Group (AIG), in addition to the launch of Mannogem XL, is building a strong pipeline of market-relevant innovative excipient platforms and dossier services to help global Pharma customers differentiate and manage their product portfolio."

The product is being showcased at CPhI Worldwide in Madrid, Spain, as well as PharmSci 360 this November in Washington, DC and CPhI India this December in New Delhi. More information can be found at www.spipharma.com, requested via salesinfo@spipharma.com, or through contacting your sales representative.

About SPI Pharma
SPI Pharma, headquartered in Wilmington, Delaware, provides innovative solutions to global pharmaceutical and nutritional customers. Product lines include Antacid Actives, Excipients, Drug Delivery Systems, Taste-Masking, and Vaccine Adjuvants. SPI Pharma specializes in drug development services, having participated in over 60 commercially launched and marketed drugs globally. Leveraging the backing of its parent company, Associated British Foods plc, and its sites in the US, France and India, the company solves the most challenging formulation problems- efficiently, cost-effectively, and with a focus on service. For further information on SPI, please visit www.spipharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/spi-pharma-launches-mannogem-xl-mannitol-enabling-production-of-difficult-to-compress-and-problematic-formulations-300726687.html

SOURCE SPI Pharma

PR Newswire
www.prnewswire.com

Last updated on: 09/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.